Immucell (ICCC) Depreciation & Amortization (CF) (2010 - 2026)
Immucell's (ICCC) quarterly Depreciation & Amortization (CF) came in at $709472.0 in Q4 2025, up 3.62% YoY from $684655.0 in Q4 2024, and little changed on a QoQ basis from $708667.0 in Q3 2025.
Immucell (ICCC) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Depreciation & Amortization (CF) data on file, last reported at $709472.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 3.62% year-over-year to $709472.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 1.98% YoY) and the FY2025 annual result came in at $2.8 million, up 1.98% from the prior year.
- Depreciation & Amortization (CF) held at $709472.0 in Q4 2025, from $708667.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $709472.0 in Q4 2025 to a low of $596424.0 in Q4 2021.
- A 5-year average of $653021.8 and a median of $662966.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) rose 11.78% — and 2024, when it decreased 2.03%.
- Tracing ICCC's Depreciation & Amortization (CF) over 5 years: stood at $596424.0 in 2021, then advanced by 0.51% to $599479.0 in 2022, then climbed by 11.78% to $670109.0 in 2023, then gained by 2.17% to $684655.0 in 2024, then gained by 3.62% to $709472.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $709472.0 (Q4 2025), $708667.0 (Q3 2025), and $663455.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | 470,621.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 470,621.00 |
| Jun 30, 2026 | 470,621.00 |
| Dec 31, 2025 | 709,472.00 |
| Dec 31, 2025 | 709,472.00 |
| Sep 30, 2025 | 708,667.00 |
| Sep 30, 2025 | 708,667.00 |
| Jun 30, 2025 | 663,455.00 |
| Jun 30, 2025 | 663,455.00 |
| Mar 31, 2025 | 671,191.00 |
| Mar 31, 2025 | 671,191.00 |
| Dec 31, 2024 | 684,655.00 |
| Dec 31, 2024 | 684,655.00 |
| Sep 30, 2024 | 685,927.00 |
| Sep 30, 2024 | 685,927.00 |
| Jun 30, 2024 | 666,182.00 |
| Jun 30, 2024 | 666,182.00 |
| Mar 31, 2024 | 662,477.00 |
| Mar 31, 2024 | 662,477.00 |
| Dec 31, 2023 | 670,109.00 |
| Dec 31, 2023 | 670,109.00 |